Pricing Log in Create free account
Saturday 17 October 2026 Export FLGT’s income statement to Excel — free account

Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Fulgent Genetics, Inc. (FLGT) Business Profile

Updated before January 2025

Company Overview

Fulgent Genetics, Inc. (NASDAQ: FLGT) is a leading technology-driven company specializing in comprehensive genetic testing and diagnostics. Founded in 2011 by Ming Hsieh, James Xie, and Brandon Perthuis, the company is headquartered in Temple City, California. Fulgent Genetics has grown rapidly since its inception, leveraging its proprietary technology platform to deliver highly accurate and customizable genetic testing solutions. The company is led by Ming Hsieh, who serves as Chairman and CEO, and James Xie, who holds the position of Chief Operating Officer. Their leadership has been instrumental in driving innovation and expanding the company’s footprint in the genetic testing industry.

Core Business Segments

Fulgent Genetics operates across several core business segments, offering a wide range of genetic testing products and services. These include:

1. Clinical Diagnostics

Fulgent provides a comprehensive suite of clinical diagnostic tests, including:

  • Next-Generation Sequencing (NGS): Advanced genetic sequencing services for identifying hereditary conditions, rare diseases, and cancer predispositions.
  • Carrier Screening: Tests designed to identify genetic conditions that could be passed on to offspring.
  • Oncology Testing: Genetic tests for cancer diagnosis, treatment planning, and monitoring.
  • Reproductive Health: Services such as preimplantation genetic testing and non-invasive prenatal testing (NIPT).

2. COVID-19 Testing

During the COVID-19 pandemic, Fulgent Genetics quickly adapted its platform to offer high-throughput COVID-19 testing. This segment includes:

  • RT-PCR Testing: Gold-standard testing for SARS-CoV-2 detection.
  • At-Home Testing Kits: Convenient options for individuals to test for COVID-19 from the comfort of their homes.
  • Corporate and Institutional Testing Programs: Tailored solutions for businesses, schools, and government agencies.

3. Research Services

Fulgent also supports academic and pharmaceutical research through:

  • Custom Panels: Tailored genetic testing panels for specific research needs.
  • Bioinformatics Solutions: Advanced data analysis tools to support genetic research.

4. Data Services

The company offers data-driven insights and analytics to healthcare providers and researchers, enabling better decision-making and personalized treatment plans.

Business Model

Fulgent Genetics operates on a hybrid business model that integrates technology, services, and data analytics. The company’s proprietary technology platform allows for high scalability, cost efficiency, and customization. Revenue is generated through:

  • Test Sales: Direct sales of genetic tests to healthcare providers, institutions, and individuals.
  • Partnerships: Collaborations with research institutions, pharmaceutical companies, and government agencies.
  • Data Licensing: Monetizing anonymized genetic data for research and development purposes.

Fulgent’s focus on innovation and operational efficiency has enabled it to maintain competitive pricing while delivering high-quality services.

Strategic Direction

Fulgent Genetics is committed to expanding its market presence and diversifying its product offerings. Key strategic initiatives include:

  • Service Expansion: Broadening the scope of genetic tests to include new areas such as pharmacogenomics and rare disease diagnostics.
  • Global Growth: Expanding operations in international markets, particularly in Asia and Europe.
  • Sustainability Goals: Implementing eco-friendly practices in its operations and supply chain.
  • Technology Advancements: Investing in artificial intelligence and machine learning to enhance test accuracy and efficiency.
  • New Product Development: Exploring opportunities in emerging fields like gene therapy and personalized medicine.

Competitive Landscape

Fulgent Genetics operates in a highly competitive market, facing competition from:

  • Myriad Genetics: A leader in hereditary cancer testing.
  • Invitae Corporation: Known for its comprehensive genetic testing services.
  • Quest Diagnostics and LabCorp: Major players in diagnostic testing with genetic testing divisions.
  • 23andMe and AncestryDNA: Consumer-focused genetic testing companies.

Fulgent differentiates itself through its proprietary technology, customizable solutions, and focus on clinical diagnostics.

Risk Factors

Despite its strengths, Fulgent Genetics faces several risks, including:

  • Market Dependence: Heavy reliance on COVID-19 testing revenue, which may decline as the pandemic subsides.
  • Regulatory Challenges: Compliance with stringent healthcare regulations and data privacy laws.
  • Supply Chain Disruptions: Potential delays in obtaining reagents and other testing materials.
  • Competition: Intense competition from established players and new entrants.
  • Economic Uncertainty: Macroeconomic factors that could impact healthcare spending.

Recent Developments

Fulgent Genetics has made significant strides in recent years, including:

  • COVID-19 Testing Expansion: Scaling up testing capacity to meet global demand during the pandemic.
  • New Product Launches: Introduction of expanded carrier screening panels and oncology-focused tests.
  • Partnerships: Collaborations with government agencies for large-scale testing programs.
  • Technological Innovations: Enhancements to its bioinformatics platform for faster and more accurate data analysis.

Investment Considerations

Strengths:

  • Innovative Technology: Proprietary platform that enables high accuracy and scalability.
  • Diverse Product Portfolio: Comprehensive range of genetic tests.
  • Strong Leadership: Experienced management team with a track record of success.
  • Growth Potential: Opportunities in emerging markets and new product categories.

Risks:

  • Revenue Concentration: Dependence on COVID-19 testing revenue.
  • Regulatory Risks: Potential challenges in navigating complex healthcare regulations.
  • Market Competition: Intense competition from established and emerging players.

Conclusion

Fulgent Genetics has established itself as a leader in the genetic testing industry, driven by its innovative technology and diverse product offerings. While the company faces challenges such as market dependence and regulatory risks, its strategic initiatives and growth potential position it well for future success. Investors should weigh the company’s strengths and risks carefully when considering it as a potential investment opportunity.